Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
On Thursday, June 4th, at the close of trading in New York, the ICE U.S. Dollar Index fell by 0.10% to 99.432 points, remaining in a downward trend throughout the day. Before 16:00 (GMT+8), it held steady around 99.450 points, then displayed a V-shaped movement, hitting a daily low of 99.179 points at 20:00.

On Thursday, June 4th, at the close of trading in New York, the ICE U.S. Dollar Index fell by 0.10% to 99.432 points, remaining in a downward trend throughout the day. Before 16:00 (GMT+8), it held steady around 99.450 points, then displayed a V-shaped movement, hitting a daily low of 99.179 points at 20:00.

华尔街见闻华尔街见闻2026/06/04 19:37
Show original
The Bloomberg Dollar Index fell by 0.06% to 1,204.71 points. In early European trading, the index briefly turned positive and reached an intraday high of 1,205.94 points at 15:41 (UTC+8). A V-shaped movement followed, and the index hit a new intraday low of 1,202.49 points at 20:00 (UTC+8).The US dollar against the Japanese yen fell by 0.03% to 160.02 yen. During a brief sharp decline, it reached a new intraday low of 159.61 yen at 12:34 (UTC+8).
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage